KORU Medical aims to broaden FreedomEDGE use beyond immunoglobulin indications to reach the oncology infusion centre market.
Hospitals given federal 340B Drug Pricing Program discounts to support their service for low-income populations marked up the cost of outpatient infusion drugs for privately insured patients ...
AUSTIN, Texas — New or soon-to-be approved drugs for conditions that require infusions, such as postpartum depression and thyroid eye disease, along with the potential for an infusible drug for ...
(CNN) — The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests, ...
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, Baptist Health South Florida, spoke about his panel held at the recent Institute for Value-Based Medicine® that The American Journal of Managed Care® ...
Some people covered by health insurer Highmark will be getting drug infusion therapy at home or a local medical office rather than at a hospital. Highmark began the program this month, saying “members ...
You've probably seen an infusion pump, even though the name might make it sound like a mysterious piece of medical technology. These devices govern the flow of IV medications and fluids into patients.
The Community Oncology Alliance (COA) said it is worried that the safety of patients with cancer will be compromised if home infusion regulatory changes, brought about by the coronavirus disease 2019 ...
Average wholesale prices (AWPs) have long been recognized as a flawed payment benchmark because they are list prices that do not reflect the real-world prices available in the marketplace. For that ...
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
It's one thing to talk about security vulnerabilities in a product, but another to provide a proof-of-concept demonstration showing the device being hacked. That's what occurred last month when ...